Life Science & Biotech

Lilly suffers another bruise from Novo

March 9, 2011
J.K. Wall
The failure of its drug Bydureon to match the performance of Novo’s Victoza trims but doesn’t kill sales prospects for the highly touted diabetes drug.
More

Lilly confident of FDA approval for Amyvid, Lechleiter says

March 9, 2011
Bloomberg News
Eli Lilly and Co. CEO John Lechleiter said he’s confident of gaining U.S. regulatory approval for a drug to help identify plaque in the brain associated with Alzheimer’s disease.
More

Dow Chemical moves toward engineered corn patent

March 1, 2011
Associated Press
Dow Chemical Co.'s agricultural division said it has taken the next step toward gaining international patent rights for its new strain of genetically engineered corn that it says will help farmers battle a new strain of "super-weeds."
More

UPDATE: Bioanalytical researcher opening lab in Indianapolis

March 1, 2011
Advion BioServices is expected to open the lab at Purdue Research Park in Indianapolis in May with 49 employees. Some of the workers may come from Eli Lilly and Co., which is moving its drug-discovery bioanalytical operations to Advion as part of a partnership.
More

Lilly looks to double pipeline size again

February 23, 2011
J.K. Wall
Indianapolis-based Lilly is developing what it calls “The Mirror Portfolio,” which it expects to grow to 45 to 60 drugs in five years. This month, Lilly announced it had secured venture-capital funding for the first two drugs in this alternative pipeline.
More

Lilly's master plan for downtown (real estate)

February 19, 2011
Cory Schouten
As Eli Lilly and Co. outsources work and sheds unnecessary properties, it is making moves with surplus real estate that could establish the strongest physical connection between Lilly and downtown since the company was founded at Pearl and Meridian streets 135 years ago.
More

Lilly collaboration with outside researchers yields first deal

February 8, 2011
Chris O'Malley
Eli Lilly and Co.'s PD2 project attracted 30,000 compounds from researchers in 26 countries. And Lilly scientist Alan Palkowitz said it's just the first of many such collaborations.
More

Struggling Lilly turns to antidepressant Cymbalta for lift

February 5, 2011
Greg Andrews
Cymbalta racked up $3.5 billion in sales last year, and some analysts say it may approach $5 billion before generic competition arrives in 2013.
More

Endocyte again changes terms of public offering

February 4, 2011
 IBJ Staff and Bloomberg News
The West Lafayette-based biopharmaceutical company now is planning to offer at least 12.5 million shares, or 17 percent more than previously announced, but at a lower price of $6 each.
More

Dow Agro's quarterly sales, profit climb

February 3, 2011
 IBJ Staff and Associated Press
Indianapolis-based Dow AgroSciences on Thursday reported record fourth-quarter revenue of $1.3 billion, up 19 percent from the prior-year period.
More

Marcadia may fetch up to $537 million in sale

February 2, 2011
J.K. Wall
The December sale of Carmel-based Marcadia Biotech to Roche garnered at least $287 million—and as much as $537 million—for the company’s owners and could lead the Marcadia management team to launch a firm using one of Marcadia’s experimental diabetes medicines.
More

Molecules are moneymakers for software firm Indigo BioSystemsRestricted Content

January 29, 2011
Chris O'Malley
Eli Lilly and Co. spin-off has landed new private investment and may double its work force this year.
More

Marketing firm VMS plans growth, new jobs

January 28, 2011
 IBJ Staff
Event-planning powerhouse VMS Inc. plans to invest more than $1.5 million to expand its Indianapolis life sciences marketing operation and create as many as 102 jobs over the next four years, state officials said Friday morning.
More

Life sciences to drive Purdue's next decade of building

January 26, 2011
J.K. Wall
Over the past 10 years, Purdue University has built Discovery Park into a thriving research and business incubation center, launching more than 30 companies and hosting dozens more. Now Purdue will spend more than $164 million to construct a Life and Health Sciences Quadrangle next to Discovery Park.
More

Lilly imaging drug fails to win FDA panel's backing

January 21, 2011
Bloomberg News
Eli Lilly and Co.'s Amyvid isn't ready to be approved to detect Alzheimer's-related deposits in the brain, according to FDA advisors. The medicine could still be approved if Lilly establishes a training program and a way to ensure that the results of brain scans are read consistently, they said.
More

Down on luck, Lilly finds comfort in pets

January 19, 2011
J.K. Wall
Eli Lilly and Co. continues to misfire on getting new human medicines approved, but its animal health unit is on a roll.
More

Endocyte prices IPO stock

January 14, 2011
J.K. Wall
The West Lafayette-based drug development firm intends to sell 6.15 million shares for $13 to $15 apiece. That would fetch $80 million to $92 million.
More

Panel says Lilly’s Solpura isn’t ready for approval

January 12, 2011
Bloomberg News
Eli Lilly and Co. failed to win an FDA advisory panel’s recommendation to introduce the first pancreatic enzyme that isn’t derived from pig parts.
More

Roche back in court as partner looks to sell to competitor

January 12, 2011
J.K. Wall
Roche Diagnostics requested a temporary restraining order against Medical Automation Systems Inc. Tuesday after receiving word the company is speeding up plans to sell itself to Roche rival Alere Inc.
More

Deal could give Lilly full diabetes deck

January 12, 2011
J.K. Wall
Eli Lilly and Co.'s diabetes partnership with Boehringer Ingelheim GmbH represents a new kind of disease-focused strategy that some consultants think is key to pharma companies’ futures.
More

UPDATE: Analysts praise Lilly diabetes deal with Boehringer

January 11, 2011
J.K. Wall
The deal Eli Lilly and Co. announced Tuesday morning with Boehringer Ingelheim GmbH sounded a lot like a baseball trade—with five drugs and payments to be named later—but analysts and investors generally liked what they heard.
More

Aprimo sale may usher in 'new wave' of tech dealsRestricted Content

January 8, 2011
Chris O'Malley
Observers say conditions are ripening for more deals like the recent $525 million sale of Aprimo Inc. in the months ahead—not only among IT firms, but also among biotech companies here.
More

Roche aims to prevent bidding war for software firm

January 7, 2011
J.K. Wall
The Swiss company, which operates its North American business out of Indianapolis, filed a lawsuit late last month against Virginia-based Medical Automation Systems Inc. for breaching the purchase agreement the companies signed back in October.
More

Roche acquires Marcadia Biotech

December 30, 2010
Chris O'Malley
Marcadia Biotech Inc., a Carmel-based biopharmaceutical company founded by prominent scientists from Eli Lilly and Co. in 2006, has been acquired by Swiss life sciences giant Roche.
More

Q&A

December 29, 2010
J.K. Wall
Bruce Frank, a former Roche Diagnostics manager, McKinsey consultant and pro basketball player, talks about changes in the medical device and life sciences industries.
More
Page  << 11 12 13 14 15 16 17 18 19 20 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. How much you wanna bet, that 70% of the jobs created there (after construction) are minimum wage? And Harvey is correct, the vast majority of residents in this project will drive to their jobs, and to think otherwise, is like Harvey says, a pipe dream. Someone working at a restaurant or retail store will not be able to afford living there. What ever happened to people who wanted to build buildings, paying for it themselves? Not a fan of these tax deals.

  2. Uh, no GeorgeP. The project is supposed to bring on 1,000 jobs and those people along with the people that will be living in the new residential will be driving to their jobs. The walkable stuff is a pipe dream. Besides, walkable is defined as having all daily necessities within 1/2 mile. That's not the case here. Never will be.

  3. Brad is on to something there. The merger of the Formula E and IndyCar Series would give IndyCar access to International markets and Formula E access the Indianapolis 500, not to mention some other events in the USA. Maybe after 2016 but before the new Dallara is rolled out for 2018. This give IndyCar two more seasons to run the DW12 and Formula E to get charged up, pun intended. Then shock the racing world, pun intended, but making the 101st Indianapolis 500 a stellar, groundbreaking event: The first all-electric Indy 500, and use that platform to promote the future of the sport.

  4. No, HarveyF, the exact opposite. Greater density and closeness to retail and everyday necessities reduces traffic. When one has to drive miles for necessities, all those cars are on the roads for many miles. When reasonable density is built, low rise in this case, in the middle of a thriving retail area, one has to drive far less, actually reducing the number of cars on the road.

  5. The Indy Star announced today the appointment of a new Beverage Reporter! So instead of insightful reports on Indy pro sports and Indiana college teams, you now get to read stories about the 432nd new brewery open or some obscure Hoosier winery winning a county fair blue ribbon. Yep, that's the coverage we Star readers crave. Not.

ADVERTISEMENT